Preferred Label : trastuzumab deruxtecan;
Obsolete resource : false;
CISMeF synonym : DS-8201a;
MeSH hyponym : DS-8201;
UNII : 5384HK7574;
Origin ID : C000614160;
UMLS CUI : C4726900;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3598458/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2-faible-ou-ultra-faible
2025
false
false
false
France
evaluation of the transparency committee
breast neoplasms
Trastuzumab
trastuzumab deruxtecan
trastuzumab
---
https://ansm.sante.fr/tableau-acces-derogatoire/enhertu-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
guidelines for drug use
Metastatic Gastric Adenocarcinoma
stomach neoplasms
adenocarcinoma
neoplasm metastasis
Locally Advanced Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
HER2/Neu Positive
trastuzumab deruxtecan
infusions, intravenous
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
breast neoplasms
Metastatic HER2-Positive Breast Carcinoma
Unresectable HER2-Positive Breast Carcinoma
Refractory HER2-Positive Breast Carcinoma
HER2-Low Breast Carcinoma
Metastatic HER2-Low Breast Carcinoma
neoplasm recurrence, local
---
https://ansm.sante.fr/tableau-marr/trastuzumab-deruxtecan
2024
false
false
false
France
French
risk management
trastuzumab deruxtecan
trastuzumab deruxtecan
infusions, intravenous
Antineoplastic Agents, Immunological
medication errors
guidelines for drug use
lung diseases
patient education handout
patients guideline
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
---
https://www.has-sante.fr/jcms/p_3530992/fr/enhertu-trastuzumab-deruxtecan-cancer-du-poumon
2024
false
false
false
France
evaluation of the transparency committee
Lung Carcinoma
neoplasm, malignant
Trastuzumab Deruxtecan
lung neoplasms
Trastuzumab Deruxtecan
trastuzumab deruxtecan
lung cancer
trastuzumab
Trastuzumab
trastuzumab deruxtecan
---
https://www.has-sante.fr/jcms/p_3443053/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
Unresectable HER2-Positive Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
neoplasm metastasis
trastuzumab deruxtecan
guidelines for drug use
Antineoplastic Agents, Immunological
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
trastuzumab deruxtecan
Trastuzumab
---
https://www.has-sante.fr/jcms/p_3424347/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2023
false
false
false
France
Metastatic HER2-Positive Breast Carcinoma
Refractory HER2-Positive Breast Carcinoma
Unresectable HER2-Positive Breast Carcinoma
Antineoplastic Agents, Immunological
receptor, erbB-2
treatment outcome
insurance, health, reimbursement
adult
trastuzumab deruxtecan
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
Trastuzumab
trastuzumab deruxtecan
---
https://www.has-sante.fr/jcms/p_3458293/fr/enhertu-trastuzumab-deruxtecan-cancer-de-l-estomac
2023
false
false
false
France
stomach neoplasms
adenocarcinoma
adult
treatment outcome
insurance, health, reimbursement
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Refractory Gastroesophageal Junction Adenocarcinoma
Refractory Gastric Adenocarcinoma
Advanced Gastric Adenocarcinoma
Antineoplastic Agents, Immunological
trastuzumab deruxtecan
evaluation of the transparency committee
trastuzumab deruxtecan
---
https://www.has-sante.fr/jcms/p_3447975/fr/enhertu-trastuzumab-deruxtecan-adenocarcinome-gastrique-ou-de-la-jonction-oesogastrique-jog
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
infusions, intravenous
stomach neoplasms
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
trastuzumab deruxtecan
insurance, health, reimbursement
---
https://www.has-sante.fr/jcms/p_3444788/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2-faible
2023
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
trastuzumab deruxtecan
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
breast neoplasms
neoplasm metastasis
Metastatic HER2-Low Breast Carcinoma
adult
Unresectable Breast Carcinoma
HER2/Neu Low Expression
infusions, intravenous
---
https://www.has-sante.fr/jcms/p_3341817/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
https://has-sante.fr/jcms/p_3341825/fr/decision-n-2022-0166/dc/sem-du-19-mai-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-enhertu
2022
false
false
false
France
camptothecin
antibodies, monoclonal, humanized
immunoconjugates
treatment outcome
insurance, health, reimbursement
Unresectable HER2-Positive Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
HER2/Neu Positive
infusions, intravenous
antineoplastic agents
trastuzumab deruxtecan
evaluation of the transparency committee
Trastuzumab
breast neoplasms
trastuzumab deruxtecan
---
https://www.has-sante.fr/jcms/p_3359829/fr/enhertu-trastuzumab-deruxtecan-cancer-estomac
2022
false
false
false
France
Antineoplastic Agents, Immunological
trastuzumab deruxtecan
antibodies, monoclonal, humanized
immunoconjugates
camptothecin
insurance, health, reimbursement
treatment outcome
stomach neoplasms
adenocarcinoma
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
esophagogastric junction
HER2/Neu Positive
HER2 positive gastric cancer
adult
infusions, intravenous
evaluation of the transparency committee
Trastuzumab
trastuzumab deruxtecan
---
https://www.has-sante.fr/jcms/p_3383475/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2-faible
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
receptor, erbB-2
HER2-Low Breast Carcinoma
Metastatic HER2-Low Breast Carcinoma
neoplasm metastasis
Unresectable
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
Trastuzumab
breast neoplasms
trastuzumab deruxtecan
---
https://www.has-sante.fr/jcms/p_3272596/fr/enhertu-trastuzumab-deruxtecan
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
trastuzumab deruxtecan
adult
breast neoplasms
HER2-Positive Breast Carcinoma
neoplasm metastasis
infusions, intravenous
evaluation of the transparency committee
trastuzumab deruxtecan
Trastuzumab
camptothecin
immunoconjugates
antibodies, monoclonal, humanized
---
https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Trastuzumab Deruxtecan
Trastuzumab Deruxtecan
drug approval
europe
trastuzumab deruxtecan
Tyrosine Kinase Inhibitors
infusions, intravenous
antineoplastic agents
pregnancy
breast feeding
drug interactions
drug monitoring
adult
breast neoplasms
neoplasm metastasis
Unresectable Breast Carcinoma
aged
receptor, erbB-2
drug evaluation, preclinical
trastuzumab deruxtecan
trastuzumab deruxtecan
antineoplastic agents
camptothecin
immunoconjugates
antibodies, monoclonal, humanized
Trastuzumab
immunoconjugates
antibodies, monoclonal, humanized
Trastuzumab
---
